Even amid a risk-averse investing environment, there’s always money available for the most innovative drug and medical device ideas, said Joseph Panetta, CEO of the San Diego-based life sciences trade group Biocom.
That was one of the core messages Panetta took away from his organization’s second annual Global Life Sciences Partnering Conference, held in Torrey Pines earlier this month. “The funding is there for companies with unique technology,” Panetta said.
Data from various economic reports released in February provide evidence that the local biotechnology industry, while not as brimming with venture capital as it once was, is still a bright spot nationally and within California when it comes to dollars and deals.
San Diego’s life sciences sector ended the year maintaining its lead position as the No. 1 sector for investment in the region, according to the MoneyTree Report from PricewaterhouseCoopers LLP and the National Venture Capital Association.
Capturing Their Attention
The sector accounted for 74 percent of total venture capital deals in San Diego in the fourth quarter, with $193 million — or 72 percent of total dollars invested — going into 69 deals, according to PricewaterhouseCoopers Partner Bill Molloie.
For all of 2011, the life sciences industry also managed to capture the largest share — 64 percent — of locally invested venture capital dollars, with a total of $534 million invested, the report said. That’s much better than the industry did nationally, garnering 27 percent of total dollars.
While the industry can’t complain about winning over the software, telecommunications and other industries, the total dollars invested in local life science companies did fall 3 percent from 2010. On the bright side: Average deal size increased slightly in 2011 to $7.7 million compared with $7.2 million the year earlier, the report said.
Domain Associates LLC was the most active venture capital firm in San Diego, with 20 local deals covering an array of industries in 2011, PricewaterhouseCoopers said in the report.
Early Stage Suffers Most
Still, local industry observers agree that early-stage funding for San Diego biotech companies continues to be a serious challenge, especially since the national appetite for initial public offerings also is down across the board — with the exception, perhaps, of social media companies such as Facebook, said David Gollaher, founder and CEO of the La Jolla-based California Healthcare Institute, a nonprofit organization for the biomedical industry.
“Our industry is constrained by the cutbacks in venture capital,” said Gollaher. “Nationally, there’s a shift of venture toward later stage products and away from early-stage investments.”
Indeed, San Diego’s biotech and medical devices got 75 percent of total early-stage investments in 2011, down from 94 percent in 2010, according to the PricewaterhouseCoopers MoneyTree Report.
Unpredictable and costly approval routes at the U.S. Food and Drug Administration are largely to blame for the decrease, Gollaher said. “Investors are reluctant with respect to how long the process will take with medical technology,” Gollaher said, citing a local example of Orexigen Therapeutics Inc.
San Diego-based Orexigen has been going back and forth with the FDA since 2010 in an effort to bring its obesity drug Contrave to market. The company is about to launch a final safety trial at the FDA’s request to rule out certain cardiovascular risks; approval may come in 2014.
Alternate Funding Routes
The cost of developing and launching a new drug is commonly cited at $1 billion, Gollaher notes. Without venture funding to help companies keep the lights on before a product reaches the market, many drugs are destined to fall into the so-called “valley of death,” Gollaher said.
More and more, life science companies are looking beyond venture funding to pay the bills during the early stage. They’re seeking partnerships with pharmaceutical companies and increasingly looking to the National Institutes of Health, a U.S. agency that provides funding for medical research and drug discovery.
Gollaher said he’s encouraged that NIH Director Francis Collins is making a public effort to focus more resources on the “valley of death” space with the goal of speeding up the time it takes for science to move from the bench to the pharmacy.
Look at All the Vital Signs
“It’s certainly been a challenging time for biotech,” said Matthew Hudes, U.S. managing principal for biotechnology at Deloitte Consulting LLP in San Francisco. “I don’t want to understate what the last three to four years have been like — a lot of volatility in an industry that’s already volatile. But you have to kind of look at the whole picture.”
Hudes said that while the early-stage funding climate has forced San Diego’s biotech scene to slow down in recent years, “it seems to have never reached the point where companies were cutting to the bone and giving away their best assets just to survive.”
Hudes characterized the local life sciences industry as “thriving” and “healthy” — attributes that come as a result of having an array of capital formation mechanisms available beyond venture capital “from licensing deals to private equity and M&A activity,” he said.
Panetta points to still other signs of health: An uptick of jobs with high-paying salaries and a thriving network of contract research organizations that are supporting the growth of biotech companies.
In Biocom’s first-ever economic impact report measuring the regional life sciences industry, the group forecasts that the San Diego County biotech companies would add 2,770 positions by the end of 2013, on top of an existing employee base of nearly 42,000.
And the industry is diverse, representing industrial biotech companies, biofuel producers, research institutes, medical device makers, drug developers, and supply distributors, Panetta said.